Savara Announces Participation in 2026 Citizens Life Sciences Conference
News > Business News
Audio By Carbonatix
4:05 PM on Wednesday, March 4
The Associated Press
LANGHORNE, Pa.--(BUSINESS WIRE)--Mar 4, 2026--
Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a fireside chat at the 2026 Citizens Life Sciences Conference on Wednesday, March 11 th at 10:10am ET in Miami, FL.
The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company’s corporate website and will be archived for 90 days.
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). Molgramostim is delivered via a proprietary investigational eFlow ® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of MOLBREEVI. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com and LinkedIn.
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.
View source version on businesswire.com:https://www.businesswire.com/news/home/20260304462858/en/
CONTACT: Media and Investor Relations Contact
Savara Inc.
Temre Johnson, Executive Director, Corporate Affairs
KEYWORD: FLORIDA PENNSYLVANIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS
SOURCE: Savara Inc.
Copyright Business Wire 2026.
PUB: 03/04/2026 04:05 PM/DISC: 03/04/2026 04:07 PM
http://www.businesswire.com/news/home/20260304462858/en
